Header Logo

DONNA M WEBER

TitleProfessor
InstitutionMD Anderson
DepartmentLymphoma-Myeloma
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Alzahrani K, Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. Br J Haematol. 2024 May; 204(5):1944-1952. PMID: 38448009; PMCID: PMC11090754.
      Citations: 1     Fields:    Translation:Humans
    2. Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Khan HN, Kebriaei P, Lee HC, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience. Blood Cancer J. 2024 01 10; 14(1):4. PMID: 38199987; PMCID: PMC10781953.
      Citations: 2     Fields:    Translation:Humans
    3. Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer. 2024 May 01; 130(9):1663-1672. PMID: 38127583; PMCID: PMC11009063.
      Citations: 2     Fields:    Translation:Humans
    4. Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplant Cell Ther. 2023 Dec; 29(12):757-762. PMID: 37673125.
      Citations: 1     Fields:    Translation:Humans
    5. Pasvolsky O, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Saeed A, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol. 2023 10; 98(10):1571-1578. PMID: 37461327; PMCID: PMC10530277.
      Citations:    Fields:    Translation:Humans
    6. Pasvolsky O, Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Tewari P, Crawford-Suber L, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of young adults (aged?=?40?years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. Br J Haematol. 2023 08; 202(4):866-873. PMID: 37376789; PMCID: PMC10527395.
      Citations:    Fields:    Translation:Humans
    7. Dang M, Wang R, Lee HC, Patel KK, Becnel MR, Han G, Thomas SK, Hao D, Chu Y, Weber DM, Lin P, Lutter-Berka Z, Berrios Nolasco DA, Huang M, Bansal H, Song X, Zhang J, Futreal A, Moreno Rueda LY, Symer DE, Green MR, Rojas Hernandez CM, Kroll M, Afshar-Khargan V, Ndacayisaba LJ, Kuhn P, Neelapu SS, Orlowski RZ, Wang L, Manasanch EE. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell. 2023 06 12; 41(6):1032-1047.e4. PMID: 37311413; PMCID: PMC10317474.
      Citations: 3     Fields:    Translation:Humans
    8. Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Champlin R, Shpall EJ, Lin P, Qazilbash MH. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J. 2023 05 03; 13(1):68. PMID: 37137874; PMCID: PMC10156676.
      Citations: 1     Fields:    Translation:HumansCells
    9. Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol. 2023 05; 201(4):e37-e41. PMID: 36916461.
      Citations:    Fields:    Translation:Humans
    10. Pasvolsky O, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Kebriaei P, Shpall EJ, Champlin RE, Gaballa MR, Milton DR, Tang G, Lin P, Lee HC, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience. Transplant Cell Ther. 2023 04; 29(4):260.e1-260.e6. PMID: 36646323; PMCID: PMC10040427.
      Citations: 2     Fields:    Translation:Humans
    11. Shank BR, Primeaux B, Yeung EK, Horowitz SB, Lee IY, Roccograndi L, Feng L, Kaufman GP, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Weber DM, Becnel MR, Thomas SK. Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis. Clin Lymphoma Myeloma Leuk. 2023 04; 23(4):279-290. PMID: 36797154; PMCID: PMC10038830.
      Citations:    Fields:    Translation:Humans
    12. Damron EP, Qazilbash MH, Fang PQ, Wu SY, Dabaja BS, Rondon G, Hosing C, Champlin RE, Bashir Q, Shpall EJ, Knafl MK, Lee HC, Manasanch EE, Patel K, Thomas SK, Orlowski RZ, Weber DM, Pinnix CC, Gunther JR. Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma. Transplant Cell Ther. 2023 01; 29(1):37.e1-37.e7. PMID: 37753818.
      Citations:    Fields:    Translation:Humans
    13. Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Tang G, Saini N, Ramdial J, Masood A, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. Transplant Cell Ther. 2022 11; 28(11):752.e1-752.e6. PMID: 35940528.
      Citations:    
    14. Afrough A, Alsfeld LC, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q, Milton DR. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplant Cell Ther. 2023 04; 29(4):264.e1-264.e9. PMID: 35605883.
      Citations:    Fields:    
    15. Gaballa MR, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman GP, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Orlowski RZ, Qazilbash MH. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant. 2022 07; 57(7):1142-1149. PMID: 35523847.
      Citations:    Fields:    Translation:Humans
    16. Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. Am J Hematol. 2022 07; 97(7):E276-E280. PMID: 35472167; PMCID: PMC10476149.
      Citations:    Fields:    Translation:Humans
    17. Patel KK, Shah JJ, Feng L, Lee HC, Manasanch EM, Olsem J, Morphey A, Huo XJ, Thomas SK, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ. Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma. Clin Cancer Res. 2022 04 01; 28(7):1277-1284. PMID: 34992070; PMCID: PMC9365361.
      Citations:    Fields:    Translation:Humans
    18. Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Delgado R, Ullah MR, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2022 06; 28(6):307.e1-307.e8. PMID: 35331973.
      Citations:    Fields:    Translation:Humans
    19. Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, Costello C, Devarakonda S, Elsedawy N, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Liedtke M, Martin T, Omel J, Sborov D, Shain K, Stockerl-Goldstein K, Weber D, Berardi RA, Kumar R, Kumar SK. NCCN Guidelines? Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw. 2022 01; 20(1):8-19. PMID: 34991075.
      Citations: 1     Fields:    Translation:Humans
    20. Srour SA, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MH, Milton DR. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica. 2021 12 01; 106(12):3211-3214. PMID: 34407606; PMCID: PMC8634193.
      Citations:    Fields:    Translation:Humans
    21. Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma. 2022 03; 63(3):710-721. PMID: 34686083.
      Citations: 1     Fields:    Translation:Humans
    22. Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MH. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol. 2021 12 01; 96(12):E455-E457. PMID: 34559916.
      Citations:    Fields:    Translation:Humans
    23. Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta R, Kaufman GP, Srour S, Saini N, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. Br J Haematol. 2021 05; 193(3):e23-e26. PMID: 33748943.
      Citations: 2     Fields:    Translation:Humans
    24. Wang Y, Gali VL, Xu-Monette ZY, Sano D, Thomas SK, Weber DM, Zhu F, Fang X, Deng M, Zhang M, Hagemeister FB, Li Y, Orlowski RZ, Lee HC, Young KH. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstr?m macroglobulinemia. Neoplasia. 2021 04; 23(4):361-374. PMID: 33735664; PMCID: PMC7985670.
      Citations: 2     Fields:    Translation:Humans
    25. Manasanch EE, Kunacheewa C, Claussen CM, Lee HC, Thomas SK, Gunther J, Pinnix CC, Dabaja BS, Amini B, Alexanian R, Orlowski RZ, Dong W, Feng L, Weber DM. Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. Blood Cancer J. 2021 02 08; 11(2):17. PMID: 33563896; PMCID: PMC7873072.
      Citations: 2     Fields:    Translation:Humans
    26. Manasanch EE, Berrios D, Fountain E, Claussen CM, Chuang T, Kaufman G, Amini B, Bashir Q, Nieto Y, Qazilbash M, Patel K, Thomas SK, Weber DM, Berkova Z, Toruner G, Lin P, Feng L, Lee HC, Orlowski RZ, Kunacheewa C. Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. Br J Haematol. 2021 02; 192(4):e115-e120. PMID: 33486754.
      Citations: 1     Fields:    Translation:HumansCells
    27. Kumar SK, Callander NS, Adekola K, Anderson L, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Kang Y, Hultcrantz M, Larson S, Liedtke M, Martin T, Omel J, Shain K, Sborov D, Stockerl-Goldstein K, Weber D, Keller J, Kumar R. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 12 02; 18(12):1685-1717. PMID: 33285522.
      Citations: 30     Fields:    Translation:HumansCells
    28. Saini N, Bashir Q, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH, Milton DR. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv. 2020 10 13; 4(19):4834-4837. PMID: 33027527; PMCID: PMC7556152.
      Citations: 1     Fields:    
    29. Hao S, Lu X, Gong Z, Bassett RL, Hu S, Konoplev SN, Tang G, Li S, Xu J, Khanlari M, Lee HC, Manasanch EE, Weber DM, Orlowski RZ, Medeiros LJ, Lin P. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma. Mod Pathol. 2021 02; 34(2):327-335. PMID: 32908255.
      Citations: 3     Fields:    Translation:Humans
    30. Manasanch EE, Mulanovich V, Manzano JG, Gaeta MS, Becnel M, Kaufman GP, Lee HC, Amini B, Thomas SK, Iyer SP, Weber DM, Berkova Z, Flowers CR, Orlowski RZ, Patel KK. SARS-CoV-2 in multiple myeloma: initial observation and management. Leuk Lymphoma. 2020 11; 61(11):2763-2766. PMID: 33167721; PMCID: PMC8092112.
      Citations: 1     Fields:    Translation:HumansCellsPHPublic Health
    31. Kunacheewa C, Lee HC, Patel K, Thomas S, Amini B, Srour S, Bashir Q, Nieto Y, Qazilbash MH, Weber DM, Feng L, Orlowski RZ, Lin P, Manasanch EE. Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. Clin Lymphoma Myeloma Leuk. 2020 05; 20(5):e221-e238. PMID: 32037287; PMCID: PMC7190410.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    32. Elhammali A, Amini B, Ludmir EB, Gunther JR, Milgrom SA, Pinnix CC, Andraos T, Yoder A, Weber D, Orlowski R, Manasanch E, Patel K, Strati P, Nair R, Lee HC, Thomas S, Iyer S, Kaufmann G, Garg N, Dabaja BS. New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. Haematologica. 2020 07; 105(7):e355-e357. PMID: 31919088; PMCID: PMC7327656.
      Citations: 5     Fields:    Translation:HumansPHPublic Health
    33. Varma A, Sui D, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH, Milton DR. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant. 2020 04; 26(4):665-671. PMID: 31881283; PMCID: PMC8365505.
      Citations: 7     Fields:    Translation:HumansCells
    34. Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 06; 26(6):1077-1083. PMID: 31786242.
      Citations: 1     Fields:    Translation:Humans
    35. Lee HC, Shah JJ, Feng L, Morphey A, Johnson RJ, Wesson ET, Wang ML, Alexanian R, Thomas SK, Orlowski RZ, Weber DM. A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Am J Hematol. 2019 12; 94(12):E319-E322. PMID: 31489991.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    36. Lee HC, Shah JJ, Feng L, Manasanch EE, Lu R, Morphey A, Crumpton B, Patel KK, Wang ML, Alexanian R, Thomas SK, Weber DM, Orlowski RZ. A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Blood Cancer J. 2019 10 01; 9(10):80. PMID: 31575851; PMCID: PMC6773683.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    37. Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R. NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. J Natl Compr Canc Netw. 2019 10 01; 17(10):1154-1165. PMID: 31590151.
      Citations: 36     Fields:    Translation:Humans
    38. Buege MJ, Do B, Lee HC, Weber DM, Horowitz SB, Feng L, Qing Y, Shank BR. Corrected calcium versus ionized calcium measurements for identifying hypercalcemia in patients with multiple myeloma. Cancer Treat Res Commun. 2019; 21:100159. PMID: 31521048; PMCID: PMC7494047.
      Citations: 2     Fields:    Translation:Humans
    39. Saini N, Ma J, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH, Milton DR. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clin Cancer Res. 2019 11 15; 25(22):6781-6787. PMID: 31481508.
      Citations: 2     Fields:    Translation:HumansCells
    40. Figgins B, Primeaux B, Shank BR, Chen SE, Weber DM, Lu H. Cyclophosphamide desensitization in patients with severe hypersensitivity reactions to bendamustine. J Oncol Pharm Pract. 2020 Jun; 26(4):982-985. PMID: 31433727.
      Citations: 1     Fields:    Translation:Humans
    41. Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Olsem J, Crumpton B, Morphey A, Berkova Z, Feng L, Orlowski RZ. Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma. Haematologica. 2020 05; 105(5):e242-e245. PMID: 31413094; PMCID: PMC7193461.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    42. Manasanch EE, Han G, Mathur R, Qing Y, Zhang Z, Lee H, Weber DM, Amini B, Berkova Z, Eterovic K, Zhang S, Zhang J, Song X, Mao X, Morgan M, Feng L, Baladandayuthapani V, Futreal A, Wang L, Neelapu SS, Orlowski RZ. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv. 2019 08 13; 3(15):2400-2408. PMID: 31405950; PMCID: PMC6693011.
      Citations: 15     Fields:    
    43. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcomes of autologous stem cell transplantation in Waldenstr?m's macroglobulinemia. Ann Hematol. 2019 Sep; 98(9):2233-2235. PMID: 31243571.
      Citations:    Fields:    Translation:Humans
    44. Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EE. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk. 2019 09; 19(9):560-569. PMID: 31201134; PMCID: PMC6713607.
      Citations: 9     Fields:    Translation:Humans
    45. Elhammali A, Milgrom SA, Amini B, Gunther JR, Yoder A, Ludmir EB, Moon B, Weber DM, Thomas SK, Garg N, Manasanch EE, Patel KK, Orlowski RZ, Lee HC, Bird JE, Satcher R, Lin P, Pinnix CC, Dabaja BS. Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated? Clin Lymphoma Myeloma Leuk. 2019 08; 19(8):e465-e469. PMID: 31133526.
      Citations: 2     Fields:    Translation:Humans
    46. Bashir Q, Thall PF, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH, Milton DR. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019 May; 6(5):e266-e275. PMID: 30910541; PMCID: PMC9446704.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    47. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol. 2019 03; 94(3):E72-E74. PMID: 30548467.
      Citations:    Fields:    Translation:HumansCells
    48. Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Feng L, Berkova Z, Hildebrandt M, Orlowski RZ. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. Lancet Haematol. 2018 Dec; 5(12):e628-e640. PMID: 30501870.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    49. Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant. 2019 07; 54(7):1089-1093. PMID: 30446740; PMCID: PMC8393277.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    50. Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol. 2019 01; 94(1):E2-E5. PMID: 30300461.
      Citations:    Fields:    Translation:Humans
    51. Chaudhry M, Steiner R, Claussen C, Patel K, Lee H, Weber D, Thomas S, Feng C, Amini B, Orlowski R, Feng L, Manasanch EE. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenstr?m's macroglobulinemia. Leuk Lymphoma. 2019 04; 60(4):964-970. PMID: 30227761.
      Citations: 3     Fields:    Translation:Humans
    52. Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Weber DM, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 11; 24(11):2197-2203. PMID: 30016656.
      Citations: 7     Fields:    Translation:Humans
    53. Hu B, Thall P, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH, Milton DR. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma. 2019 02; 60(2):442-452. PMID: 30032678.
      Citations: 8     Fields:    Translation:Humans
    54. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. J Natl Compr Canc Netw. 2018 01; 16(1):11-20. PMID: 29295877.
      Citations: 38     Fields:    Translation:Humans
    55. Purushothaman A, Bandari SK, Chandrashekar DS, Jones RJ, Lee HC, Weber DM, Orlowski RZ. Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes. Oncotarget. 2017 Sep 26; 8(43):73723-73732. PMID: 29088739; PMCID: PMC5650294.
      Citations: 8     Fields:    
    56. Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leuk Lymphoma. 2018 02; 59(2):515-518. PMID: 28673185.
      Citations: 1     Fields:    Translation:Humans
    57. Hao S, Lin P, Medeiros LJ, Fang L, Carballo-Zarate AA, Konoplev SN, Sargent RL, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Lu X. Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion. Mod Pathol. 2017 10; 30(10):1378-1386. PMID: 28664940; PMCID: PMC5628266.
      Citations:    Fields:    Translation:Humans
    58. Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE, Gandhi V, Orlowski RZ. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol. 2017 Jun; 96(6):977-985. PMID: 28337527; PMCID: PMC5406425.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    59. Carballo-Zarate AA, Medeiros LJ, Fang L, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Hao S, Shen Q, Orlowski RZ, Lin P, Lu X. Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience. Mod Pathol. 2017 06; 30(6):843-853. PMID: 28281554.
      Citations: 4     Fields:    Translation:HumansCells
    60. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 02; 15(2):230-269. PMID: 28188192.
      Citations: 57     Fields:    Translation:Humans
    61. Lee HC, Weber DM. Advances and practical use of monoclonal antibodies in multiple myeloma therapy. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):512-520. PMID: 27913523; PMCID: PMC6142433.
      Citations: 2     Fields:    Translation:Humans
    62. Jones RJ, Iempridee T, Wang X, Lee HC, Mertz JE, Kenney SC, Lin HC, Baladandayuthapani V, Dawson CW, Shah JJ, Weber DM, Orlowski RZ. Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression. Clin Cancer Res. 2016 Oct 01; 22(19):4901-4912. PMID: 27297582; PMCID: PMC5050094.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    63. Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DW, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ, Milan E, Cenci S. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell. 2016 05 09; 29(5):639-652. PMID: 27132469; PMCID: PMC4983190.
      Citations: 46     Fields:    Translation:HumansAnimalsCells
    64. Alsina M, Atanackovic D, Biermann JS, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Shead DA, Kumar R, Anderson KC, Chandler JC, Treon SP. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. J Natl Compr Canc Netw. 2016 04; 14(4):389-400. PMID: 27059188; PMCID: PMC6016087.
      Citations: 23     Fields:    Translation:Humans
    65. Badar T, Cornelison AM, Shah ND, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. Eur J Haematol. 2016 Oct; 97(4):342-7. PMID: 26773409.
      Citations: 2     Fields:    Translation:Humans
    66. Shah JJ, Feng L, Thomas SK, Berkova Z, Weber DM, Wang M, Qazilbash MH, Champlin RE, Mendoza TR, Cleeland C, Orlowski RZ. Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer J. 2016 Feb 12; 6:e396. PMID: 26871714; PMCID: PMC4771967.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    67. Cao X, Medeiros LJ, Xia Y, Wang X, Thomas SK, Loghavi S, Li X, Shah JJ, Gustafson SA, Weber DM, Miranda RN, Xu-Monette ZY, Orlowski RZ, Young KH. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma. 2016 May; 57(5):1104-13. PMID: 26421453.
      Citations: 10     Fields:    Translation:Humans
    68. Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2016 Jan; 16(1):36-42. PMID: 26702475.
      Citations: 1     Fields:    Translation:Humans
    69. Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R, National Comprehensive Cancer Network. Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2015 Nov; 13(11):1398-435. PMID: 26553768; PMCID: PMC4891187.
      Citations: 22     Fields:    Translation:Humans
    70. Kanagal-Shamanna R, Xu-Monette ZY, Miranda RN, Dogan A, Zou D, Luthra R, Weber DM, O'Malley DP, Jorgensen JL, Khoury JD, Bueso-Ramos CE, Orlowski RZ, Medeiros LJ, Young KH. Crystal-storing histiocytosis: a clinicopathological study of 13 cases. Histopathology. 2016 Mar; 68(4):482-91. PMID: 26118455; PMCID: PMC4704983.
      Citations: 20     Fields:    Translation:HumansCells
    71. Cao X, Ye Q, Orlowski RZ, Wang X, Loghavi S, Tu M, Thomas SK, Shan J, Li S, Qazilbash M, Yin CC, Weber D, Miranda RN, Xu-Monette ZY, Medeiros LJ, Young KH. Waldenstr?m macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol. 2015 Jun 24; 8:74. PMID: 26104577; PMCID: PMC4487966.
      Citations: 2     Fields:    Translation:Humans
    72. Abudayyeh A, Truong LD, Beck LH, Weber DM, Rezvani K, Abdelrahim M. Membranous nephropathy in autologous hematopoietic stem cell transplant: autologous graft-versus-host disease or autoimmunity induction? Clin Kidney J. 2015 Aug; 8(4):440-4. PMID: 26251713; PMCID: PMC4515891.
      Citations: 5     
    73. Kuiatse I, Baladandayuthapani V, Lin HY, Thomas SK, Bjorklund CC, Weber DM, Wang M, Shah JJ, Zhang XD, Jones RJ, Ansell SM, Yang G, Treon SP, Orlowski RZ. Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenstr?m Macroglobulinemia. Clin Cancer Res. 2015 Jun 01; 21(11):2538-45. PMID: 25748087; PMCID: PMC4737551.
      Citations: 10     Fields:    Translation:HumansCells
    74. Liu Z, Xu J, He J, Zheng Y, Li H, Lu Y, Qian J, Lin P, Weber DM, Yang J, Yi Q. A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. Blood. 2014 Sep 25; 124(13):2061-71. PMID: 25049282; PMCID: PMC4186536.
      Citations: 47     Fields:    Translation:HumansAnimalsCells
    75. Wuu A, Bangert SD, Weber DM, Hymes SR. Primary cutaneous plasmacytoma. Cutis. 2014 Jun; 93(6):E19-21. PMID: 24999652.
      Citations: 1     Fields:    Translation:Humans
    76. Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang M. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol. 2014 May 09; 7:41. PMID: 24886772; PMCID: PMC4038108.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    77. Alexanian R, Wang M, Delasalle K, Wang S, Qazilbash M, Handy B, Weber D. Value of novel agents and intensive therapy for patients with multiple myeloma. Bone Marrow Transplant. 2014 Mar; 49(3):422-5. PMID: 24317125.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    78. Cardoso RC, Gerngross PJ, Hofstede TM, Weber DM, Chambers MS. The multiple oral presentations of multiple myeloma. Support Care Cancer. 2014 Jan; 22(1):259-67. PMID: 24048519; PMCID: PMC6248880.
      Citations: 8     Fields:    Translation:Humans
    79. Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley CS, Lonial S. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013 Oct 03; 122(14):2331-7. PMID: 23950178.
      Citations: 128     Fields:    Translation:HumansCTClinical Trials
    80. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia. 2014 Feb; 28(2):373-83. PMID: 23760401; PMCID: PMC3874423.
      Citations: 50     Fields:    Translation:HumansAnimalsCells
    81. Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications. Exp Hematol. 2013 Aug; 41(8):719-30. PMID: 23648290; PMCID: PMC3769691.
      Citations: 8     Fields:    Translation:HumansCells
    82. Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Illizaliturri F, Huff CA, Kassim A, Krishnan AY, Liedtke M, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Yunus F, Shead DA, Kumar R. Multiple myeloma, version 1.2013. J Natl Compr Canc Netw. 2013 Jan 01; 11(1):11-7. PMID: 23307977.
      Citations: 22     Fields:    Translation:Humans
    83. Weber DM, Graef T, Hussein M, Sobecks RM, Schiller GJ, Lupinacci L, Hardwick JS, Jagannath S. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):319-24. PMID: 23040438.
      Citations: 18     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    84. Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA, NCCN (National Comprehensive Cancer Network). Waldenstr?m's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Canc Netw. 2012 Oct 01; 10(10):1211-9. PMID: 23054875.
      Citations: 10     Fields:    Translation:Humans
    85. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. 2012 Oct 18; 120(16):3260-70. PMID: 22932796; PMCID: PMC3476538.
      Citations: 88     Fields:    Translation:HumansAnimalsCells
    86. Chanan-Khan AA, Lonial S, Weber D, Borrello I, Hellmann A, Dimopoulos M, Swern AS, Knight R, Fo? R. Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients =65 years old with relapsed or refractory multiple myeloma. Int J Hematol. 2012 Aug; 96(2):254-62. PMID: 22752567; PMCID: PMC3670754.
      Citations: 3     Fields:    Translation:Humans
    87. Alexanian R, Delasalle K, Wang M, Thomas S, Weber D. Curability of multiple myeloma. Bone Marrow Res. 2012; 2012:916479. PMID: 22675638; PMCID: PMC3366198.
      Citations: 15     
    88. Sweeney SA, Kumar VA, Tayar J, Weber DM, Safdar A, Alonso C, Hymes S. Case 181: synovitis acne pustulosis hyperostosis osteitis (SAPHO) syndrome. Radiology. 2012 May; 263(2):613-7. PMID: 22517965.
      Citations: 4     Fields:    Translation:Humans
    89. Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R, Morgan GJ. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood. 2012 Mar 22; 119(12):2764-7. PMID: 22323483.
      Citations: 44     Fields:    Translation:Humans
    90. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2012 Mar; 87(3):272-6. PMID: 22231283; PMCID: PMC3894831.
      Citations: 10     Fields:    Translation:Humans
    91. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, National Comprehensive Cancer Network. Multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1146-83. PMID: 21975914.
      Citations: 24     Fields:    Translation:Humans
    92. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplant in patients aged =70 years with multiple myeloma. Leuk Lymphoma. 2012 Jan; 53(1):118-22. PMID: 21780997.
      Citations: 30     Fields:    Translation:Humans
    93. Dimopoulos MA, Hussein M, Swern AS, Weber D. Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. Leukemia. 2011 Oct; 25(10):1620-6. PMID: 21747400; PMCID: PMC3194066.
      Citations: 9     Fields:    Translation:Humans
    94. Ishak KJ, Caro JJ, Drayson MT, Dimopoulos M, Weber D, Augustson B, Child JA, Knight R, Iqbal G, Dunn J, Shearer A, Morgan G. Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma. Value Health. 2011 Jul-Aug; 14(5):672-8. PMID: 21839405.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    95. Reed V, Shah J, Medeiros LJ, Ha CS, Mazloom A, Weber DM, Arzu IY, Orlowski RZ, Thomas SK, Shihadeh F, Alexanian R, Dabaja BS. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer. 2011 Oct 01; 117(19):4468-74. PMID: 21437886.
      Citations: 34     Fields:    Translation:Humans
    96. Dimopoulos MA, Stadtmauer EA, Rajkumar SV, Siegel D, Bravo ML, Olesnyckyj M, Knight RD, Zeldis JB, Harousseau JL, Weber DM, San-Miguel JF. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):38-43. PMID: 21273172.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    97. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol. 2011 Mar; 152(5):579-92. PMID: 21241278; PMCID: PMC3402914.
      Citations: 29     Fields:    Translation:HumansCells
    98. Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JJ, Zhang L, Lu G, Zhao M, Muddasani R, Yoo SY, Baggerly KA, Orlowski RZ. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. Oncogene. 2011 Mar 17; 30(11):1329-40. PMID: 21057542; PMCID: PMC4128235.
      Citations: 23     Fields:    Translation:HumansCells
    99. Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE. Effect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol Biomarkers Prev. 2010 Oct; 19(10):2445-52. PMID: 20805315; PMCID: PMC2966770.
      Citations: 26     Fields:    Translation:HumansCells
    100. Dimopoulos M, Alegre A, Stadtmauer EA, Goldschmidt H, Zonder JA, de Castro CM, Masliak Z, Reece D, Olesnyckyj M, Yu Z, Weber DM. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer. 2010 Aug 15; 116(16):3807-14. PMID: 20564094; PMCID: PMC2970911.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    101. Dimopoulos MA, Wang M, Corso A, Chen C, Attal M, Spencer A, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM, Harousseau JL. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica. 2010 Oct; 95(10):1738-44. PMID: 20460639; PMCID: PMC2948100.
      Citations: 33     Fields:    Translation:Humans
    102. Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol. 2010 Jul; 150(1):28-38. PMID: 20507313.
      Citations: 30     Fields:    Translation:HumansPHPublic Health
    103. Richards T, Weber D. Advances in treatment for relapses and refractory multiple myeloma. Med Oncol. 2010 Jun; 27 Suppl 1:S25-42. PMID: 20213220.
      Citations: 4     Fields:    Translation:Humans
    104. Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, Fu T, Weber D, Dimopoulos MA, Niesvizky R, Fink L. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol. 2010 Jan 01; 28(1):132-5. PMID: 19901114.
      Citations: 19     Fields:    Translation:Humans
    105. Thomas SK, Richards TA, Weber DM. Novel agents for relapsed and/or refractory multiple myeloma. Cancer J. 2009 Nov-Dec; 15(6):485-93. PMID: 20010168.
      Citations: 1     Fields:    Translation:Humans
    106. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom J, Yunus F, National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):908-42. PMID: 19878637.
      Citations: 50     Fields:    Translation:Humans
    107. Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009 Nov; 23(11):2147-52. PMID: 19626046.
      Citations: 109     Fields:    Translation:Humans
    108. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MH. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jul; 15(7):812-6. PMID: 19539212; PMCID: PMC4112358.
      Citations: 17     Fields:    Translation:HumansAnimalsCTClinical Trials
    109. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S, K?rbling M. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jun; 15(6):718-23. PMID: 19450756; PMCID: PMC4352933.
      Citations: 39     Fields:    Translation:Humans
    110. Stadtmauer EA, Weber DM, Niesvizky R, Belch A, Prince MH, Facon T, Olesnyckyj M, Yu Z, Zeldis JB, Knight RD, Dimopoulos MA, San Miguel JF. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol. 2009 Jun; 82(6):426-32. PMID: 19302559; PMCID: PMC2704925.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    111. Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant. 2008 Dec; 14(12):1401-7. PMID: 19041063; PMCID: PMC4112362.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    112. Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 2008 Dec 01; 112(12):4445-51. PMID: 18799726.
      Citations: 53     Fields:    Translation:Humans
    113. Campagnaro E, Saliba R, Giralt S, Roden L, Mendoza F, Aleman A, Cleeland C, Weber D, Brown J, Anderson KO. Symptom burden after autologous stem cell transplantation for multiple myeloma. Cancer. 2008 Apr 01; 112(7):1617-24. PMID: 18260091.
      Citations: 17     Fields:    Translation:Humans
    114. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA, International Myeloma Working Group, Blad? J. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008 Feb; 22(2):414-23. PMID: 18094721.
      Citations: 197     Fields:    Translation:Humans
    115. Thomas SK, Richards TA, Weber DM. Lenalidomide in multiple myeloma. Best Pract Res Clin Haematol. 2007 Dec; 20(4):717-35. PMID: 18070715.
      Citations: 1     Fields:    Translation:Humans
    116. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD, Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22; 357(21):2133-42. PMID: 18032763.
      Citations: 362     Fields:    Translation:HumansCTClinical Trials
    117. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P, ASH/FDA Panel on Clinical Endpoints in Multiple Myeloma. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008 Feb; 22(2):231-9. PMID: 17972944.
      Citations: 84     Fields:    Translation:Humans
    118. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant. 2007 Sep; 13(9):1066-72. PMID: 17697969.
      Citations: 13     Fields:    Translation:HumansCells
    119. Christoforidou AV, Saliba RM, Williams P, Qazilbash M, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Wendt R, Breitz H, Alexanian R, Champlin R, Giralt S. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biol Blood Marrow Transplant. 2007 May; 13(5):543-9. PMID: 17448913.
      Citations: 6     Fields:    Translation:Humans
    120. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL, De Castro CM, Djulbegovic B, Farag S, Huff CA, Meredith R, Schriber J, Shrieve D, Singhal S, Smith MR, Stockerl-Goldstein K, Vose JM, Weber D, Yahalom J, Yunus F, National Comprehensive Cancer Network (NCCN). Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Feb; 5(2):118-47. PMID: 17335683.
      Citations: 17     Fields:    Translation:Humans
    121. Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant. 2007 Mar; 39(5):279-83. PMID: 17262062.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    122. Qazilbash MH, Saliba RM, Aleman A, Lei X, Weber D, Carrasco A, Champlin RE, Giralt SA. Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leuk Lymphoma. 2006 Jul; 47(7):1360-4. PMID: 16923569.
      Citations: 3     Fields:    Translation:Humans
    123. Merzianu M, Jiang L, Lin P, Wang X, Weber DM, Vadhan-Raj S, Nguyen MH, Medeiros LJ, Bueso-Ramos CE. Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenstr?m macroglobulinemia and does not correlate with p65 NF-kappaB activation. Mod Pathol. 2006 Jul; 19(7):891-8. PMID: 16636680.
      Citations: 4     Fields:    Translation:HumansCells
    124. Donato ML, Feasel AM, Weber DM, Prieto VG, Giralt SA, Champlin RE, Duvic M. Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood. 2006 Jan 15; 107(2):463-6. PMID: 16179379; PMCID: PMC1895605.
      Citations: 11     Fields:    Translation:Humans
    125. Moulopoulos LA, Gika D, Anagnostopoulos A, Delasalle K, Weber D, Alexanian R, Dimopoulos MA. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol. 2005 Nov; 16(11):1824-8. PMID: 16087694.
      Citations: 27     Fields:    Translation:Humans
    126. Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D, Alexanian R, Talpaz M, Aggarwal BB, Estrov Z. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer. 2005 Jul 11; 93(1):70-80. PMID: 15970928; PMCID: PMC2361492.
      Citations: 31     Fields:    Translation:HumansCells
    127. Wang M, Weber DM, Delasalle K, Alexanian R. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol. 2005 Jul; 79(3):194-7. PMID: 15981221.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    128. Weber DM. Solitary bone and extramedullary plasmacytoma. Hematology Am Soc Hematol Educ Program. 2005; 373-6. PMID: 16304406.
      Citations: 45     Fields:    Translation:Humans
    129. Dimopoulos MA, Alexanian R, Gika D, Anagnostopoulos A, Zervas C, Zomas A, Kyrtsonis MC, Anagnostopoulos N, Pangalis GA, Weber DM. Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression. Leuk Lymphoma. 2004 Oct; 45(10):2057-61. PMID: 15370250.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    130. Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D, Alexanian R, Giralt S. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer. 2004 Jun 15; 100(12):2607-12. PMID: 15197803.
      Citations: 21     Fields:    Translation:Humans
    131. Donato ML, Aleman A, Champlin RE, Weber D, Alexanian R, Ippoliti CM, de Lima M, Anagnostopoulos A, Giralt S. High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma. Leuk Lymphoma. 2004 Apr; 45(4):755-9. PMID: 15160952.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    132. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood. 2004 Apr 15; 103(8):3175-84. PMID: 15070700.
      Citations: 122     Fields:    Translation:HumansCells
    133. Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol. 2003 Dec 01; 21(23):4444-54. PMID: 14645435.
      Citations: 18     Fields:    Translation:Humans
    134. Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol. 2003 Oct; 40(4 Suppl 4):3-7. PMID: 15015890.
      Citations: 3     Fields:    Translation:Humans
    135. Ahmed M, Giles F, Joe Y, Weber DM, Jilani I, Manshouri T, Giralt S, De Lima M, Keating M, Albitar M. Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma. Eur J Haematol. 2003 Sep; 71(3):174-8. PMID: 12930317.
      Citations: 4     Fields:    Translation:HumansCells
    136. Weber D. Thalidomide and its derivatives: new promise for multiple myeloma. Cancer Control. 2003 Sep-Oct; 10(5):375-83. PMID: 14581892.
      Citations: 5     Fields:    Translation:Humans
    137. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol. 2003 Jun; 121(5):768-71. PMID: 12780791.
      Citations: 26     Fields:    Translation:Humans
    138. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003 Jun; 121(5):749-57. PMID: 12780789.
      Citations: 710     Fields:    Translation:Humans
    139. Weber DM. Strategies in treating newly diagnosed or untreated multiple myeloma patients. From the Multiple Myeloma Research Foundation. Oncology (Williston Park). 2003 Jun; 17(6):765-7. PMID: 12846120.
      Citations:    Fields:    Translation:Humans
    140. Giralt S, Bensinger W, Goodman M, Podoloff D, Eary J, Wendt R, Alexanian R, Weber D, Maloney D, Holmberg L, Rajandran J, Breitz H, Ghalie R, Champlin R. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood. 2003 Oct 01; 102(7):2684-91. PMID: 12730103.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    141. Alexanian R, Weber D, Delasalle K, Cabanillas F, Dimopoulos M. Asymptomatic Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):206-10. PMID: 12720137.
      Citations: 9     Fields:    Translation:Humans
    142. Weber D, Treon SP, Emmanouilides C, Branagan AR, Byrd JC, Kimby E, Blad? J. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):127-31. PMID: 12720121.
      Citations: 9     Fields:    Translation:Humans
    143. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):243-7. PMID: 12720145.
      Citations: 12     Fields:    Translation:Humans
    144. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003 Jan 01; 21(1):16-9. PMID: 12506164.
      Citations: 84     Fields:    Translation:HumansCTClinical Trials
    145. Alexanian R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol. 2002 Jul; 13(7):1116-9. PMID: 12176792.
      Citations: 7     Fields:    Translation:Humans
    146. Weber DM. Newly diagnosed multiple myeloma. Curr Treat Options Oncol. 2002 Jun; 3(3):235-45. PMID: 12057069.
      Citations: 1     Fields:    Translation:Humans
    147. Wilder RB, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer. 2002 Mar 01; 94(5):1532-7. PMID: 11920511.
      Citations: 29     Fields:    Translation:Humans
    148. Alexanian R, Weber D. Recent advances in treatment of multiple myeloma and Waldenstr?m's macroglobulinemia. Biomed Pharmacother. 2001 Nov; 55(9-10):550-2. PMID: 11769965.
      Citations:    Fields:    Translation:Humans
    149. Mansoor A, Medeiros LJ, Weber DM, Alexanian R, Hayes K, Jones D, Lai R, Glassman A, Bueso-Ramos CE. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenstr?m macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol. 2001 Oct; 116(4):543-9. PMID: 11601139.
      Citations: 12     Fields:    Translation:HumansCells
    150. Hoque A, Lippman SM, Boiko IV, Atkinson EN, Sneige N, Sahin A, Weber DM, Risin S, Lagios MD, Schwarting R, Colburn WJ, Dhingra K, Follen M, Kelloff GJ, Boone CW, Hittelman WN. Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 2001 Mar; 10(3):249-59. PMID: 11303595.
      Citations: 14     Fields:    Translation:HumansCells
    151. Younes A, Cristofanilli M, McLaughlin P, Hagemeister FB, Weber D, Mesina O, Cabanillas F. Experience with 9-cis retinoic acid in patients with relapsed and refractory non-Hodgkin's lymphoma. Leuk Lymphoma. 2000 Dec; 40(1-2):79-85. PMID: 11426631.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    152. Alexanian R, Weber D, Dimopoulos M, Delasalle K, Smith TL. Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma. Am J Hematol. 2000 Nov; 65(3):204-9. PMID: 11074536.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    153. Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol. 1999 Sep; 52(3):245-9. PMID: 10580871.
      Citations: 67     Fields:    Translation:HumansCells
    154. Siddique I, Papadakis KA, Weber DM, Glober G. Recurrent bleeding from a duodenal plasmacytoma treated successfully with embolization of the gastroduodenal artery. Am J Gastroenterol. 1999 Jun; 94(6):1691-2. PMID: 10364048.
      Citations: 2     Fields:    Translation:Humans
    155. Alexanian R, Weber D, Liu F. Differential diagnosis of monoclonal gammopathies. Arch Pathol Lab Med. 1999 Feb; 123(2):108-13. PMID: 10050782.
      Citations: 9     Fields:    Translation:Humans
    156. Romaguera JE, Hagemeister FB, McLaughlin P, Rodriguez MA, Bachier C, Preti H, Sarris AH, Weber D, Younes A, Cabanillas F. Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma. Leuk Lymphoma. 1998 Dec; 32(1-2):97-106. PMID: 10037005.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    157. NCCN practice guidelines for multiple myeloma. National Comprehensive Cancer Network. Oncology (Williston Park). 1998 Nov; 12(11A):317-51. PMID: 10028515.
      Citations: 1     Fields:    Translation:Humans
    158. Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys. 1998 Jul 15; 41(5):1063-7. PMID: 9719116.
      Citations: 36     Fields:    Translation:Humans
    159. Seong C, Delasalle K, Hayes K, Weber D, Dimopoulos M, Swantkowski J, Huh Y, Glassman A, Champlin R, Alexanian R. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol. 1998 Apr; 101(1):189-94. PMID: 9576200.
      Citations: 11     Fields:    Translation:HumansCells
    160. Weber DM, Dimopoulos MA, Moulopoulos LA, Delasalle KB, Smith T, Alexanian R. Prognostic features of asymptomatic multiple myeloma. Br J Haematol. 1997 Jun; 97(4):810-4. PMID: 9217181.
      Citations: 20     Fields:    Translation:Humans
    161. Giralt S, Weber D, Colome M, Dimopoulos M, Mehra R, Van Besien K, Gajewski J, Andersson B, Khouri I, Przepiorka D, von Wolff B, Delasalle K, Korbling M, Seong D, Alexanian R, Champlin R. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol. 1997 Feb; 15(2):667-73. PMID: 9053492.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    162. Dimopoulos MA, Weber D, Kantarjian H, Delasalle KB, Alexanian R. HyperCVAD for VAD-resistant multiple myeloma. Am J Hematol. 1996 Jun; 52(2):77-81. PMID: 8638645.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    163. Alexanian R, Weber D. Whither interferon for myeloma and other hematologic malignancies? Ann Intern Med. 1996 Jan 15; 124(2):264-5. PMID: 8534004.
      Citations: 2     Fields:    Translation:Humans
    164. Daliani D, Weber D, Alexanian R. Light-heavy chain deposition disease progressing to multiple myeloma. Am J Hematol. 1995 Dec; 50(4):296-8. PMID: 7485106.
      Citations: 2     Fields:    Translation:HumansCells
    165. Telen MJ. Clinical problem-solving: costly errors. N Engl J Med. 1995 Oct 19; 333(16):1080-1. PMID: 7675064.
      Citations:    Fields:    Translation:Humans
    166. Weber DM, Daliani D, Alexanian R. Clinical problem-solving: costly errors. N Engl J Med. 1995 Oct 19; 333(16):1080; author reply 1081. PMID: 7675063.
      Citations:    Fields:    Translation:Humans
    167. Vernon SW, Yeomans AC, Frankowski R, Weber D, Vogel VG. Behavioral and social factors that predict participation in the Breast Cancer Prevention Trial. Ann N Y Acad Sci. 1995 Sep 30; 768:300. PMID: 8526373.
      Citations: 1     Fields:    Translation:Humans
    168. Weber D, Dimopoulos M, Sinicrope F, Alexanian R. VAD-cyclosporine therapy for VAD-resistant multiple myeloma. Leuk Lymphoma. 1995 Sep; 19(1-2):159-63. PMID: 8574163.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    169. Yeomans-Kinney A, Vernon SW, Frankowski RF, Weber DM, Bitsura JM, Vogel VG. Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment. Cancer. 1995 Jul 01; 76(1):46-56. PMID: 8630876.
      Citations: 12     Fields:    Translation:Humans
    170. Moulopoulos LA, Dimopoulos MA, Smith TL, Weber DM, Delasalle KB, Libshitz HI, Alexanian R. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol. 1995 Jan; 13(1):251-6. PMID: 7799027.
      Citations: 39     Fields:    Translation:Humans
    171. Dimopoulos MA, Weber D, Delasalle KB, Keating M, Alexanian R. Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol. 1995 Jan; 6(1):49-52. PMID: 7710983.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    172. Dimopoulos MA, Kantarjian H, Weber D, O'Brien S, Estey E, Delasalle K, Rose E, Cabanillas F, Keating M, Alexanian R. Primary therapy of Waldenstr?m's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol. 1994 Dec; 12(12):2694-8. PMID: 7989946.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    173. Weber DM, Dimopoulos MA, Anandu DP, Pugh WC, Steinbach G. Regression of gastric lymphoma of mucosa-associated lymphoid tissue with antibiotic therapy for Helicobacter pylori. Gastroenterology. 1994 Dec; 107(6):1835-8. PMID: 7958698.
      Citations: 22     Fields:    Translation:HumansCells
    174. Dimopoulos MA, Arbuck S, Huber M, Weber D, Luckett R, Delasalle K, Alexanian R. Primary therapy of multiple myeloma with paclitaxel (taxol). Ann Oncol. 1994 Oct; 5(8):757-9. PMID: 7826909.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    175. Dimopoulos MA, Weber DM, Hester J, Delasalle K, Champlin R, Alexanian R. Intensive sequential therapy for VAD-resistant multiple myeloma. Leuk Lymphoma. 1994 May; 13(5-6):479-84. PMID: 7915163.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    176. Dimopoulos MA, Weber DM, Kantarjian H, Keating M, Alexanian R. 2Chlorodeoxyadenosine therapy of patients with Waldenstr?m macroglobulinemia previously treated with fludarabine. Ann Oncol. 1994 Mar; 5(3):288-9. PMID: 7514439.
      Citations: 5     Fields:    Translation:Humans
    177. Dimopoulos MA, Weber D, Delasalle KB, Alexanian R. Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma. Cancer. 1993 Nov 01; 72(9):2589-92. PMID: 8402480.
      Citations: 2     Fields:    Translation:Humans
    178. Dimopoulos MA, Weber DM, Estey EE, Alexanian R. Primary treatment with 2-chlorodeoxyadenosine of low grade lymphomas that produce IgG or IgA immunoglobulin. Am J Hematol. 1993 Aug; 43(4):326-7. PMID: 8103966.
      Citations:    Fields:    Translation:Humans
    179. Moulopoulos LA, Dimopoulos MA, Weber D, Fuller L, Libshitz HI, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol. 1993 Jul; 11(7):1311-5. PMID: 8315427.
      Citations: 33     Fields:    Translation:Humans
    180. Weber DM, Dimopoulos MA, Alexanian R. Increased neurotoxicity with VAD-cyclosporin in multiple myeloma. Lancet. 1993 Feb 27; 341(8844):558-9. PMID: 8094795.
      Citations: 1     Fields:    Translation:Humans
    181. Case 181. Radiology. 262:361-363.
    182. Filgrastim alone versus chemotherapy plis filgrastim for peripheral blood stem cell mobilization in multiple myeloma. Blood. 96.
    183. Multiple myeloma. 263-269.
    184. NCCN guidelines® insights multiple myeloma, version 3.2016 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network. 14:389-400.
    185. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer Journal. 4.
    186. Catheter-associated left-sided valvular endocarditis due to Corynebacterium striatum. Cancer Bulletin. 45:460-464.
    187. Lymphoplasmacytic lymphoma/waldenstrom's macroglobulinemia-βone marrow morphology identifies a subset of patients with accelerated clinical course. Blood. 96.
    188. The multiple oral presentations of multiple myeloma. Supportive Care in Cancer. 22:259-267.
    189. Thalidombde with dexamethasone for resistant multiple myeloma. Blood. 96.
    190. Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. Journal of Hematology and Oncology. 8.
    191. Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma (mm). Blood. 96.
    192. Membranous nephropathy in autologous hematopoietic stem cell transplant. CKJ: Clinical Kidney Journal. 8:440-444.
    193. Myeloma and leukemia. 509-529.
    194. Lenalidomide, thalidomide, and pomalidomide reactivate the Epstein-Barr virus lytic cycle through phosphoinositide 3-kinase signaling and ikaros expression. Clinical Cancer Research. 22:4901-4912.
    195. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell.
    196. Abnormal serum protein electrophoresis. Unknown Journal. 264-267.
    197. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia.
    198. Crystal-storing histiocytosis. Histopathology. 68:482-491.
    199. Thalidomide for resistant and relapsing myeloma. Seminars in Hematology. 37:22-25.
    200. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leukemia and Lymphoma. 1-10.
    201. Prognostic features of asymptomatic multiple myeloma. Cancer Research Therapy and Control. 6:113.
    202. Targeting the spleen tyrosine kinase with fostamatinib as a strategy against Waldenström Macroglobulinemia. Clinical Cancer Research. 21:2538-2545.
    203. American Society of Hematology 49th Annual Meeting. P and T. 33:111.
    204. Multiple myeloma, version 2.2016. JNCCN Journal of the National Comprehensive Cancer Network. 13:1398-1435.
    205. Magnetic resonance imaging of the bone marrow in plasma cell dyscrasias. Cancer Research Therapy and Control. 6:91-92.
    206. Reply. Gastroenterology. 109:334-335.
    WEBER's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (522)
    Explore
    _
    Co-Authors (99)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _